Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration...

17

Transcript of Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration...

Page 1: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 2: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 3: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 4: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 5: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 6: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 7: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 8: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 9: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 10: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 11: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 12: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 13: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 14: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 15: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 16: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination
Page 17: Monthly Prescribing Referencemedia.empr.com/documents/187/cotellic_46673.pdfDosage & Administration Confirm presence of BRAF V600E or V600K mutation prior to initiation In combination

Brand name: Auvi-Q - Monthly Prescribing Referencemedia.empr.com/documents/264/yondelis_65839.pdf · Dosage & Administration Give by IV infusion over 24 hours 1.5mg/m² every 21 days

Brand name: Auvi-Q - Monthly Prescribing Referencemedia.empr.com/documents/264/yondelis_65839.pdf · Dosage & Administration Give by IV infusion over 24 hours 1.5mg/m² every 21 days

BRAF V600E Mouse Monoclonal Primary Antibody

BRAF V600E Mouse Monoclonal Primary Antibody

BRAF immunohistochemistry predicts sentinel lymph node ... · and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further analyzed the correlations in

BRAF immunohistochemistry predicts sentinel lymph node ... · and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further analyzed the correlations in

BRAF V600E Mutation Detection Using High Resolution …cdn.intechopen.com/pdfs/37264.pdf · High Resolution Probe Melting Analysis ... Polymerase Chain Reaction ... BRAF V600E Mutation

BRAF V600E Mutation Detection Using High Resolution …cdn.intechopen.com/pdfs/37264.pdf · High Resolution Probe Melting Analysis ... Polymerase Chain Reaction ... BRAF V600E Mutation

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse ... · Anti-BRAF V600E (VE1) Immunohistochemistry All 120 cases were examined for presence of BRAF V600E mutationbyIHCusingtheanti-BRAFV600E(VE1)antibody

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse ... · Anti-BRAF V600E (VE1) Immunohistochemistry All 120 cases were examined for presence of BRAF V600E mutationbyIHCusingtheanti-BRAFV600E(VE1)antibody

Brief Report: Anaplastic PleomorphicXanthoastrocytoma ......and classified the tumor as a Pleomorphic Xanthoastrocytoma. Sanger sequencing detected a proto-oncogene (BRAF V600E) point

Brief Report: Anaplastic PleomorphicXanthoastrocytoma ......and classified the tumor as a Pleomorphic Xanthoastrocytoma. Sanger sequencing detected a proto-oncogene (BRAF V600E) point

Relevance and clinicopathologic relationship of BRAF V600E ...

Relevance and clinicopathologic relationship of BRAF V600E ...

Detection of the BRAF c.1799T>A (V600E) Mutation in Melanoma

Detection of the BRAF c.1799T>A (V600E) Mutation in Melanoma

Austedo - Monthly Prescribing Referencemedia.empr.com/documents/298/austedo_74255.pdfNew Product Slideshow Austedo (deutetrabenazine) Introduction Brand name: Austedo Generic name:

Austedo - Monthly Prescribing Referencemedia.empr.com/documents/298/austedo_74255.pdfNew Product Slideshow Austedo (deutetrabenazine) Introduction Brand name: Austedo Generic name:

Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E

Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E

Detection of BRAF V600E in cancers: Focus on BRAF V600E (VE1) Mouse Monoclonal Primary Antibody scientific overview

Detection of BRAF V600E in cancers: Focus on BRAF V600E (VE1) Mouse Monoclonal Primary Antibody scientific overview

Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.

Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.

BRAF V600E and decreased NIS and thyroid microcarcinoma

BRAF V600E and decreased NIS and thyroid microcarcinoma

BRAF-mutated pleomorphic xanthoastrocytoma is associated ...download.xuebalib.com/2avAEY7Mir4.pdf · brain tumor, BRAF V600E, CDKN2A, CD34, immunohistochemistry, pleomorphic xanthoastrocytoma,

BRAF-mutated pleomorphic xanthoastrocytoma is associated ...download.xuebalib.com/2avAEY7Mir4.pdf · brain tumor, BRAF V600E, CDKN2A, CD34, immunohistochemistry, pleomorphic xanthoastrocytoma,

Successful re-treatment of a relapsed V600E mutated … re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib Caroline Bailleux1,*, Guillaume Robert2,3,*,

Successful re-treatment of a relapsed V600E mutated … re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib Caroline Bailleux1,*, Guillaume Robert2,3,*,

BRAF overexpression is associated with BRAF V600E mutation ... · BRAF overexpression was detected in 55 patients with PTC (47.4%) and the BRAF V600E mutation was observed in 74 patients

BRAF overexpression is associated with BRAF V600E mutation ... · BRAF overexpression was detected in 55 patients with PTC (47.4%) and the BRAF V600E mutation was observed in 74 patients

Alunbrig - Monthly Prescribing Referencemedia.empr.com/documents/309/alunbrig_77036.pdf · Resume at reduced doses upon recovery to Grade 1 or baseline; permanently discontinue for

Alunbrig - Monthly Prescribing Referencemedia.empr.com/documents/309/alunbrig_77036.pdf · Resume at reduced doses upon recovery to Grade 1 or baseline; permanently discontinue for

Case Report Metastatic salivary ductal carcinoma androgen ... · Metastatic salivary ductal carcinoma androgen receptor-positive with V600E BRAF gene mutation Rossella De Cecio 1,

Case Report Metastatic salivary ductal carcinoma androgen ... · Metastatic salivary ductal carcinoma androgen receptor-positive with V600E BRAF gene mutation Rossella De Cecio 1,

HCC: immunohistochemistry Fall... · 53% had BRAF V600E mutation Pujals, Histopathol 2015 53% positive for VE1 antibody by immunohistochemistry Angkathunyakul, Histopathol 2017 87.5%

HCC: immunohistochemistry Fall... · 53% had BRAF V600E mutation Pujals, Histopathol 2015 53% positive for VE1 antibody by immunohistochemistry Angkathunyakul, Histopathol 2017 87.5%

SKMEL-19: T1799A (V600E), homozygous GTG -> GAG Supplemental Figure 1. Representative Mass Spectrometry and Sanger traces for the SKMEL-19 and SKMEL-32.

SKMEL-19: T1799A (V600E), homozygous GTG -> GAG Supplemental Figure 1. Representative Mass Spectrometry and Sanger traces for the SKMEL-19 and SKMEL-32.